BioSpace News Archive

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced a poster presentation at the 2021 Academy of Managed Care Pharmacy Virtual Annual Meeting (“AMCP”) taking place April 12-16, 2021.

Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the launch of its BEAT®diabetes app on the GooglePlay and iOS platforms.

Serimmune, Inc., a leader in understanding the functional antibody repertoire’s role in human disease, announced today that the company is enrolling 2,000 research participants in a study designed to understand the human immune response to SARS-CoV-2, the virus that causes COVID-19

Candel Therapeutics, a clinical-stage biotechnology company developing novel immune-based cancer therapeutics, announced the initial formation of its Research Advisory Board with the appointment of James Allison, Ph.D., Henry Brem, M.D., Roy S. Herbst, M.D., Ph.D., Elizabeth Jaffee, M.D., Philip Kantoff, M.D., and Padmanee Sharma, M.D., Ph.D., who will join existing scientific advisor and board member Edward Benz, M.D.

New studies mark an important advancement of Boehringer Ingelheim’s cardiometabolic focus areas obesity and NASH. The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on both chronic weight management and NASH improvement.

Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, today announced it has closed a $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.

CeQur®, a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the close of an oversubscribed $115 million equity financing

– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs – – Deep experience spanning drug development, manufacturing, quality and supply chain